Lab
Uva Culpeper Medical Center
Uva Culpeper Medical Center was paid $53.94M by Medicaid between Jan 2018 and Dec 2024, across 309 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoUVA CULPEPER MEDICAL CENTER
CULPEPER, VA 22701
CULPEPER, VA 22701
33aNPI1669538047assigned 12/29/2006
33bProvider typeClinical Medical Laboratory
28Total paid$53.94M
24GClaims1,045,825
24DCodes billed309
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#2 of 78
Median peer was paid$37K
This provider vs. median1,464×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CODER, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 112,331 | $2.91M | |
| 2019 | 158,518 | $5.07M | |
| 2020 | 137,868 | $5.14M | |
| 2021 | 159,224 | $5.87M | |
| 2022 | 168,008 | $9.57M | |
| 2023 | 165,217 | $14.20M | |
| 2024incomplete | 144,659 | $11.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 29,657 | 24,546 | $6.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 23,146 | 20,533 | $5.56M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.6% | 32,806 | 25,422 | $5.18M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.1% | 19,699 | 17,803 | $4.36M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.5% | 10,813 | 9,228 | $2.96M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.4% | 10,057 | 8,422 | $2.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 8,993 | 7,922 | $2.55M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.5% | 39,292 | 10,433 | $2.42M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 8,629 | 7,650 | $2.31M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 5,199 | 4,662 | $1.44M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.6% | 10,548 | 3,152 | $1.40M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.4% | 7,307 | 5,543 | $1.28M |
297 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 5,534 | $1.14M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 5,545 | $1.01M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 5,672 | $926K |
| 59025 | Fetal non-stress test | 1.3% | 2,841 | $691K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.3% | 3,248 | $688K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,322 | $626K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,695 | $582K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,289 | $510K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,308 | $506K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12,304 | $500K |
| G0378 | Hospital observation service, per hour | <1% | 3,311 | $466K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,951 | $464K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 768 | $442K |
| 87631 | <1% | 7,805 | $340K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,099 | $337K |
| 20610 | <1% | 1,209 | $315K | |
| 97161 | <1% | 2,111 | $275K | |
| 80053 | Comprehensive metabolic panel | <1% | 48,589 | $272K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,354 | $260K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,160 | $234K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 915 | $227K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,350 | $218K |
| 76801 | <1% | 2,136 | $211K | |
| 93971 | <1% | 1,521 | $182K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 709 | $177K |
| 97163 | <1% | 1,917 | $142K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,440 | $139K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,550 | $125K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,071 | $116K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 385 | $107K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,740 | $99K |
| 96367 | <1% | 1,503 | $92K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 45,103 | $81K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,614 | $79K |
| 96415 | <1% | 171 | $77K | |
| 64483 | <1% | 56 | $72K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 978 | $72K |
| 76830 | Ultrasound, transvaginal | <1% | 710 | $71K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,170 | $69K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 55 | $66K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,192 | $65K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,436 | $65K |
| 90715 | <1% | 2,143 | $56K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,245 | $54K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,122 | $50K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,656 | $48K |
| 80061 | Lipid panel | <1% | 8,815 | $47K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,683 | $47K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,131 | $46K |
| 84703 | <1% | 13,258 | $41K | |
| 93976 | <1% | 315 | $37K | |
| 97165 | <1% | 197 | $35K | |
| 83880 | <1% | 3,930 | $35K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 653 | $34K |
| 84439 | <1% | 3,857 | $33K | |
| 73630 | <1% | 2,534 | $28K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 14,845 | $28K |
| 85027 | <1% | 18,496 | $27K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,136 | $26K |
| 97116 | <1% | 1,172 | $26K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 275 | $26K |
| 86803 | <1% | 3,140 | $26K | |
| 73610 | <1% | 2,380 | $25K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,580 | $24K |
| 93017 | <1% | 221 | $24K | |
| 82607 | <1% | 2,395 | $23K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 218 | $23K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 93 | $22K |
| 73030 | <1% | 1,890 | $21K | |
| 96368 | <1% | 1,106 | $21K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,169 | $20K |
| 82728 | <1% | 3,171 | $20K | |
| 87040 | <1% | 2,502 | $20K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 370 | $17K |
| 72110 | <1% | 1,075 | $17K | |
| 73564 | <1% | 2,625 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 310 | $16K |
| 84484 | <1% | 13,317 | $16K | |
| 93000 | <1% | 11,032 | $15K | |
| 73130 | <1% | 1,570 | $15K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 481 | $15K |
| 81003 | <1% | 13,070 | $15K | |
| 84466 | <1% | 3,428 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,434 | $14K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,363 | $13K |
| 70496 | <1% | 28 | $13K | |
| 72100 | <1% | 1,193 | $13K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,598 | $13K |
| 86780 | <1% | 2,450 | $12K | |
| 76770 | <1% | 105 | $12K | |
| 73110 | <1% | 1,214 | $12K | |
| 87081 | <1% | 4,820 | $11K | |
| 97162 | <1% | 75 | $11K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,204 | $11K |
| 84481 | <1% | 141 | $10K | |
| 84702 | <1% | 2,179 | $10K | |
| 83540 | <1% | 3,639 | $10K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,939 | $10K |
| 82948 | <1% | 8,776 | $9K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,617 | $9K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 2,240 | $9K |
| 12001 | <1% | 43 | $9K | |
| 0352U | <1% | 978 | $9K | |
| 85379 | <1% | 1,898 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 900 | $9K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 610 | $9K |
| 74018 | <1% | 757 | $8K | |
| 86850 | <1% | 4,673 | $8K | |
| 80329 | <1% | 785 | $8K | |
| 29125 | <1% | 57 | $8K | |
| 82570 | <1% | 2,116 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 118 | $8K |
| 80076 | <1% | 1,868 | $7K | |
| 92523 | <1% | 40 | $7K | |
| 83735 | <1% | 8,247 | $7K | |
| J3490 | Unclassified drugs | <1% | 15,332 | $7K |
| 10060 | <1% | 27 | $7K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 31 | $7K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 88 | $7K |
| 84146 | <1% | 315 | $6K | |
| 87340 | <1% | 3,791 | $6K | |
| 86140 | <1% | 1,523 | $6K | |
| 82746 | <1% | 1,519 | $6K | |
| 76642 | <1% | 49 | $6K | |
| 97167 | <1% | 40 | $6K | |
| 83605 | <1% | 3,858 | $5K | |
| 82951 | <1% | 593 | $5K | |
| 85610 | <1% | 4,962 | $5K | |
| 81025 | <1% | 2,559 | $5K | |
| 81001 | <1% | 15,207 | $5K | |
| 96376 | <1% | 5,913 | $4K | |
| 80306 | <1% | 2,311 | $4K | |
| 87507 | <1% | 42 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,188 | $4K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14,703 | $4K |
| 80320 | <1% | 1,917 | $4K | |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | <1% | 263 | $3K |
| 73080 | <1% | 246 | $3K | |
| 82043 | <1% | 978 | $3K | |
| 84403 | <1% | 345 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 753 | $3K |
| 85652 | <1% | 1,411 | $3K | |
| 86900 | <1% | 3,821 | $3K | |
| 87186 | <1% | 3,121 | $3K | |
| 12011 | <1% | 12 | $3K | |
| 73140 | <1% | 158 | $3K | |
| 72040 | <1% | 201 | $3K | |
| 90686 | <1% | 85 | $3K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,418 | $2K |
| 82247 | <1% | 315 | $2K | |
| 73502 | <1% | 374 | $2K | |
| 73562 | <1% | 139 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,592 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 429 | $2K |
| 93970 | <1% | 12 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 337 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 903 | $2K |
| 81511 | <1% | 12 | $2K | |
| 83690 | <1% | 9,808 | $2K | |
| 82248 | <1% | 329 | $2K | |
| 87480 | <1% | 89 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,933 | $2K |
| A9270 | Non-covered item or service | <1% | 82,516 | $2K |
| 86901 | <1% | 3,829 | $2K | |
| 87088 | <1% | 2,225 | $2K | |
| 86704 | <1% | 414 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,978 | $1K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 14 | $1K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 324 | $1K |
| 84100 | <1% | 1,487 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 121 | $1K |
| 90656 | <1% | 46 | $1K | |
| 85045 | <1% | 881 | $1K | |
| 88342 | <1% | 153 | $1K | |
| 82977 | <1% | 173 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 312 | $1K |
| 72050 | <1% | 55 | $1K | |
| 86706 | <1% | 431 | $989.34 | |
| 85730 | <1% | 2,199 | $986.83 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 49 | $979.40 |
| 88142 | <1% | 491 | $968.64 | |
| 84550 | <1% | 767 | $895.01 | |
| 83001 | <1% | 159 | $886.55 | |
| 82803 | <1% | 1,974 | $818.55 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,380 | $796.05 |
| 72131 | <1% | 17 | $790.82 | |
| 70486 | <1% | 13 | $784.65 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 769 | $765.07 |
| 73560 | <1% | 220 | $721.48 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,305 | $709.09 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 12 | $705.68 |
| 87077 | <1% | 400 | $702.45 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 21 | $663.03 |
| 70498 | <1% | 27 | $582.48 | |
| 82962 | <1% | 2,200 | $582.24 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,950 | $557.82 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,238 | $507.32 |
| 85007 | <1% | 263 | $491.13 | |
| 83615 | <1% | 560 | $476.51 | |
| 73590 | <1% | 127 | $471.09 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 42 | $466.68 |
| 83525 | <1% | 85 | $459.92 | |
| 84156 | <1% | 444 | $458.01 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,487 | $451.26 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 629 | $448.51 |
| 73090 | <1% | 111 | $400.04 | |
| 82550 | <1% | 451 | $357.26 | |
| 86762 | <1% | 263 | $306.52 | |
| 86709 | <1% | 46 | $281.71 | |
| 82950 | <1% | 301 | $279.02 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,172 | $274.95 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,264 | $273.85 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 441 | $249.29 |
| 86787 | <1% | 306 | $234.97 | |
| 87070 | <1% | 146 | $222.54 | |
| 85651 | <1% | 152 | $220.66 | |
| 83655 | <1% | 39 | $212.76 | |
| 83020 | <1% | 59 | $209.02 | |
| 84270 | <1% | 32 | $181.23 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,041 | $178.69 |
| 87205 | <1% | 398 | $171.72 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,222 | $163.73 |
| 86038 | <1% | 13 | $150.20 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,926 | $148.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,293 | $146.34 |
| 84450 | <1% | 28 | $129.85 | |
| 82565 | <1% | 198 | $128.52 | |
| 82670 | <1% | 26 | $123.76 | |
| 87807 | <1% | 364 | $112.79 | |
| 84153 | <1% | 12 | $112.14 | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 41 | $91.34 |
| 85014 | <1% | 278 | $85.52 | |
| 86885 | <1% | 300 | $84.76 | |
| 87660 | <1% | 89 | $82.33 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,226 | $81.84 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,064 | $80.20 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 967 | $79.28 |
| 84402 | <1% | 14 | $71.66 | |
| 84460 | <1% | 15 | $70.21 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 185 | $65.60 |
| 87210 | <1% | 156 | $50.46 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 866 | $48.54 |
| 80050 | General health panel | <1% | 12 | $47.32 |
| 82272 | <1% | 46 | $43.61 | |
| 87510 | <1% | 89 | $43.29 | |
| 85018 | <1% | 329 | $41.75 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 419 | $41.01 |
| 82150 | <1% | 14 | $38.19 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 305 | $36.58 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 240 | $22.86 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 300 | $20.78 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 161 | $18.21 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 334 | $17.76 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,098 | $5.76 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 860 | $4.14 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 121 | $2.22 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 157 | $1.77 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 70 | $1.57 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 56 | $1.29 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 17 | $1.08 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 50 | $1.00 |
| 84132 | <1% | 17 | $0.95 | |
| 94760 | <1% | 1,564 | $0.68 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 445 | $0.15 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 150 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 191 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 31 | $0.00 |
| 88304 | 0% | 13 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 14 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 667 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 39 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 212 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 161 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 38 | $0.00 |
| 73501 | 0% | 13 | $0.00 | |
| C1769 | Guide wire | 0% | 38 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 18 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 171 | $0.00 |
| 87147 | 0% | 13 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,542 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 68 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 15 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 59 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 477 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 515 | $0.00 |
| 82009 | 0% | 16 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 205 | $0.00 |
| 80179 | 0% | 597 | $0.00 | |
| 76000 | 0% | 26 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 148 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 144 | $0.00 |
| 80143 | 0% | 362 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 48 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| 84295 | 0% | 13 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 16 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCODER, CHARLES (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.